Bladder and Bone Effects of Pelvic Radiation Therapy in Childhood Cancer Survivors
NCT ID: NCT05818462
Last Updated: 2026-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
32 participants
OBSERVATIONAL
2023-07-11
2025-05-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neoadjuvant Radiotherapy for High-risk UTUC
NCT06472752
Bone Toxicity Following Pelvic Radiotherapy
NCT04555317
SBRT for Organ Confined Prostate Cancer
NCT02653248
Evaluation of Bladder Volumes in Patients Receiving Radiotherapy to the Rectum, Using Kilovoltage Cone-beam Imaging
NCT01033682
Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis
NCT01757717
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients who received EBRT to the pelvis.
Childhood cancer survivors who were treated with chemotherapy and radiation therapy to the pelvis, with or without surgical intervention. This group will consist of both primary pelvic sarcomas as well as patients who received whole abdominal radiation that included bladder exposure.
Uroflow testing
Uroflowmetry is a test that measures the volume of urine released from the body, the speed with which it is released, and how long the release takes.
Bladder Scan
Bladder scan measures ultrasonic reflections within the patient's body to differentiate the urinary bladder from the surrounding tissue. In this case, it is used to detect the volume of urine in the bladder.
Dysfunctional Voiding Scoring System Survey
The Dysfunctional Voiding Symptom Score to provide accurate and objective numerical, grading of voiding behaviors of children.
DEXA Scan of pelvis and sacral spine
DEXA (dual x-ray absorptiometry) scans measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip and the spine.
Urine tests for specific biomarkers
Urine tests for specific biomarkers (ATP, NGF, BNDF and urine proteomic screening).
Control cohort.
Childhood cancer survivors who have been treated for a sarcoma who did not receive pelvic radiation, and were treated with chemotherapy, with or without surgical intervention or radiation therapy (outside of the pelvis). These patients will be matched as closely as possible to Group 1 to match chemotherapy regimens, and sex.
Uroflow testing
Uroflowmetry is a test that measures the volume of urine released from the body, the speed with which it is released, and how long the release takes.
Bladder Scan
Bladder scan measures ultrasonic reflections within the patient's body to differentiate the urinary bladder from the surrounding tissue. In this case, it is used to detect the volume of urine in the bladder.
Dysfunctional Voiding Scoring System Survey
The Dysfunctional Voiding Symptom Score to provide accurate and objective numerical, grading of voiding behaviors of children.
DEXA Scan of pelvis and sacral spine
DEXA (dual x-ray absorptiometry) scans measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip and the spine.
Urine tests for specific biomarkers
Urine tests for specific biomarkers (ATP, NGF, BNDF and urine proteomic screening).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Uroflow testing
Uroflowmetry is a test that measures the volume of urine released from the body, the speed with which it is released, and how long the release takes.
Bladder Scan
Bladder scan measures ultrasonic reflections within the patient's body to differentiate the urinary bladder from the surrounding tissue. In this case, it is used to detect the volume of urine in the bladder.
Dysfunctional Voiding Scoring System Survey
The Dysfunctional Voiding Symptom Score to provide accurate and objective numerical, grading of voiding behaviors of children.
DEXA Scan of pelvis and sacral spine
DEXA (dual x-ray absorptiometry) scans measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip and the spine.
Urine tests for specific biomarkers
Urine tests for specific biomarkers (ATP, NGF, BNDF and urine proteomic screening).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with tumor resection of bladder, prostate or gynecologic organs will be excluded.
2 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Colorado, Denver
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Edwards, MD
Role: PRINCIPAL_INVESTIGATOR
Children's Hospital Colorado
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Colorado Research Center
Aurora, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22-1533.cc
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.